LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

38.65 -0.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

38.33

Max

39.22

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	12.278 76.798
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+18.47% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	554M 2.2B
Ankstesnė atidarymo kaina	39.24
Ankstesnė uždarymo kaina	38.65

Naujienos nuotaikos

By Acuity

21%

79%

46 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-17 23:50; UTC

Karštos akcijos

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

2025-12-17 23:20; UTC

Uždarbis

Correction to Micron Logs Sales Jump Article

2025-12-17 23:07; UTC

Uždarbis

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

2025-12-17 21:37; UTC

Uždarbis

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

2025-12-17 23:53; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

2025-12-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

2025-12-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

2025-12-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

2025-12-17 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

2025-12-17 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

2025-12-17 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

2025-12-17 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

2025-12-17 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

2025-12-17 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

2025-12-17 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

2025-12-17 22:49; UTC

Rinkos pokalbiai

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

2025-12-17 21:58; UTC

Uždarbis

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-17 21:46; UTC

Uždarbis

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

2025-12-17 21:20; UTC

Uždarbis

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:10; UTC

Uždarbis

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:05; UTC

Uždarbis

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

2025-12-17 21:04; UTC

Uždarbis

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

2025-12-17 21:04; UTC

Uždarbis

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

2025-12-17 21:02; UTC

Uždarbis

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

2025-12-17 21:01; UTC

Uždarbis

Micron Technology 1Q Rev $13.64B >MU

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

18.47% į viršų

12 mėnesių prognozė

Vidutinis 46 USD 18.47%

Aukščiausias 62 USD

Žemiausias 32 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

46 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.